Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: HDT BIO CORP
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-09-01 to 2023-10-31
Current total value of award: $10970058
Description: COVID-19. TO DEVELOP AND PROGRESS HDT-301, A REPLICON RNA ENCODING SARS-COV-2 SPIKE PROTEIN BOUND TO LIPID INORGANIC NANOPARTICLE (LION) FORMULATION TO PROTECT AGAINST COVID-19, THROUGH A PHASE I CLINICAL TRIAL.